HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Adjuvant Treatment of Colorectal Cancer Submit a letter to the editor View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolpin, B. M. Articles by Mayer, R. J. Search for Related Content PubMed PubMed Citation Articles by Wolpin, B. M. Articles by Mayer, R. J.

Adjuvant Treatment of Colorectal Cancer

Dr. Wolpin is Instructor in Medicine, Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA.
Dr. Meyerhardt is Assistant Professor of Medicine, Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA.
Dr. Mamon is Assistant Professor of Radiation Oncology and Clinical Director, Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Dr. Mayer is Professor of Medicine and Director, Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA.

This article is available online at http://CAonline.AmCancerSoc.org
To earn free CME credit for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org

Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer-related death. Approximately three quarters of patients are diagnosed with disease limited to the bowel wall or surrounding lymph nodes. Over the past decade, significant progress has been made in the treatment of localized colorectal cancer due to advances in surgery, radiotherapy, and chemotherapy. For patients with Stage III colon cancer, an overall survival benefit for fluorouracil-based chemotherapy has been firmly established, and recent data have shown further efficacy through the inclusion of oxaliplatin into adjuvant treatment programs. For patients with Stage II colon cancer, the use of adjuvant chemotherapy remains controversial, but may be appropriate in a subset of individuals at high risk for disease recurrence. In the treatment of patients with rectal cancer, improved outcomes have been noted with the use of total mesorectal excision and preoperative concurrent chemoradiotherapy. Current randomized clinical trials in the adjuvant therapy of colorectal cancer are examining the value of adding agents known to be active in metastatic disease, including those that modify specific molecular targets.

This article has been cited by other articles:

				I. Zlobec, L. M. Terracciano, and A. Lugli Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes Clin. Cancer Res., June 15, 2008; 14(12): 3792 - 3797. [Abstract] [Full Text] [PDF]

				E. C. de Bruin, C. J.H. van de Velde, J. H. J.M. van Krieken, C. A.M. Marijnen, and J. P. Medema Epithelial Human Leukocyte Antigen-DR Expression Predicts Reduced Recurrence Rates and Prolonged Survival in Rectal Cancer Patients Clin. Cancer Res., February 15, 2008; 14(4): 1073 - 1079. [Abstract] [Full Text] [PDF]

eLetters: